Loading
MT-303 is an experimental in vivo CAR therapy from CREATE Medicines, in phase 1 trials for liver cancer (hepatocellular carcinoma).
MT-303 is an in vivo CAR therapy: mRNA in lipid nanoparticles that programmes myeloid cells from CREATE Medicines. Messenger RNA in lipid nanoparticles makes the patient's own myeloid cells, in the blood and inside the tumour, carry a chimeric antigen receptor against GPC3. The phase 1 study NCT06478693 is recruiting people with hepatocellular carcinoma, including a first-line group given MT-303 with atezolizumab and bevacizumab (first patient dosed, announced December 2025). The registry still names the sponsor by the company's former name, Myeloid Therapeutics. Whether it works in people has not been established.
Messenger RNA in lipid nanoparticles makes the patient's own myeloid cells, in the blood and inside the tumour, carry a chimeric antigen receptor against GPC3. Connects to Glypican-3.
1.MT-303 slips into a pocket on Glypican-3.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MT-303" OR ABSTRACT:"MT-303") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MT-303, not a curated reading list.
Shares Glypican-3, Hepatocellular carcinoma and the tag pipeline.
Shares Glypican-3, Hepatocellular carcinoma and the tag pipeline.
Shares CREATE Medicines and the tag pipeline.
Shares CREATE Medicines and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/